Search Results

You are looking at 71 - 80 of 517 items for :

  • Refine by Access: All x
Clear All
Full access

Giuseppe Curigliano

in all geo-cultural groups are particularly traumatized by the overt physical changes from breast cancer treatments. The stigmata of breast surgery and of treatment-related side effects such as hair loss and fatigue confirm to women the reality of

Full access

Agnes Smaradottir, Angela L. Smith, Andrew J. Borgert, and Kurt R. Oettel

mentioned fatigue most often as a significant barrier to exercise (50%). Other barriers included symptoms of disease, such as dyspnea, pain, and impaired mobility. Side effects of treatment, including nausea, vomiting, diarrhea, neuropathic pain, emotional

Full access

Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell

survival. 1 Proposed mechanisms for this positive effect on chemotherapy treatment tolerance include exercise-related amelioration of specific symptoms or toxicities that cause treatment reductions or delays, including neutropenia, fatigue, and neuropathy

Full access

Paul F. Engstrom

Full access

Lindsey A. Kluck and Ronald S. Go

Re: Sriram Yennurajalingam, Nizar M. Tannir, Janet L. Williams, et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients with Advanced Cancer. J Natl Compr Canc Netw 2017

Full access

Susana M. Campos, Mei Sheng Duh, Patrick Lefebvre, and James Rosberg

. Factors influencing quality of life in cancer patents: anemia and fatigue . Semin Oncol 1998 ; 25 : 43 – 46 . 4 Curt GA . Impact of fatigue on quality of life in oncology patients . Semin Hematol 2000 ; 37 : 14 – 17 . 5 Sobrero

Full access

Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Mishal Shaukat, and Qian Zhang

.11) Figure 1 . Paobinostat had a significantly lower risk of lymphopenia (OR 0.25 95% CI 0.15-0.42, p=<0.0001) Panobinostat was however, associated with two times more risk of anemia (OR 2.82 95% CI 1.82-4.38, p=<0.0001), fatigue (OR 2.36 95% CI 1.64-3.38, p

Full access

Daniel Shasha, Pierre Cremieux, and Louis Harrison

patients undergoing radiation therapy . Semin Oncol 2001 ; 28 ( suppl 8 ): 54 – 59 . 4 Irvine D Vincent L Graydon JE . The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy: A comparison

Full access

Mustafa Özgüroğlu, Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş, Igor Bondarenko, Miranda Gogishvili, Xuanyao He, Jennifer McGinniss, Giuseppe Gullo, Petra Rietschel, and Ruben GW Quek

statistically significant favorable difference in overall change from baseline in role functioning (8.59; 95% CI, 0.16, 17.01; p=0.0459), emotional functioning (7.27; 95% CI, 1.86, 12.69; p=0.0095), and symptoms of fatigue (-8.19; 95% CI, -15.40, -0.98; p=0

Full access

Sri Harsha Tella, Jaclynn Wessling, Foster Nathan, Shi Qian, Tran Nguyen, Robert McWillimas, Alberts Steven, Minetta Liu, Mitesh Borad, Wen Wee Ma, Mindy Hartgers, Leslie Washburn, Fruth Briant, Martin Fernandezzapico, Tara L Hogenson, Henry Pitot, Zhaohui Jin, and Amit Mahipal

(11%), fatigue (7%), and diarrhea (7%). 9 out of 27 (33%) and 14/27 (52%) had dose reductions secondary to AEs (cytopenias and fatigue) for trifluridine/tipiracil and irinotecan, respectively and 1 patient discontinued the therapy due to adverse events